Search

Outpatient ablation therapy with low-dose radioactive iodine (RAI) is applied to non-low-risk papillary thyroid cancer patients due to a chronic shortage of inpatient RAI treatment wards in Japan. We used the maximum dosage available for outpatient therapy of 30 mCi of RAI for ablation and diagnostic (Dx) whole-body scintigraphy (WBS). This study aimed to examine the significance of the second dose of 30 mCi. DxWBS was performed 6 months after ablation, and assessment of success or failure was performed 12 months after ablation. A second WBS was performed in the remaining RAI accumulation cases in the neck on DxWBS. The criteria for successful ablation was negative cervical accumulation on WBS, thyroid stimulating hormone-suppressed thyroglobulin (sup-Tg) below 1.0 ng/mL, and no increase in thyroglobulin antibody (TgAb) level. At the time of DxWBS, 35/68 cases met the successful criteria, and 45 cases achieved success at assessment. Sup-Tg values decreased significantly after ablation and decreased further after DxWBS in successful ablation cases, whereas those were not changed in ablation failure cases. Findings indicated that RAI used in DxWBS had therapeutic effects. It makes sense to use 30 mCi for DxWBS, given the current difficulty of inpatient ablation therapy with high-dose RAI. [ABSTRACT FROM AUTHOR]

The release of radioactive iodine after a nuclear disaster, such as those that occurred at the Fukushima Daiichi Nuclear Power Plant in Japan 10 years ago and Three Mile Island in Pennsylvania in 1979, increases thyroid cancer risk among people who are exposed. Certain populations are especially vulnerable, including pregnant and breastfeeding women, children, and neonates. Potassium iodide (KI) can effectively block radioactive iodine from being absorbed by the thyroid gland if taken immediately after a radiation release. This article examines lessons learned from Fukushima to enhance disaster readiness and nursing actions. Nurses should be directly involved in vulnerability assessments, emergency planning, and in ensuring the availability, accessibility, and distribution of KI within U.S. nuclear power plant emergency planning zones before a crisis occurs. [ABSTRACT FROM AUTHOR]

The Fukushima Dai-ichi Nuclear Power Plant accidents following the March 11, 2011 Tohoku earthquake, and subsequent tsunami released radioactive materials into the atmosphere and caused significant public health concerns, particularly thyroid cancers in children. However, the lack of measurement data for atmospheric concentrations of 131 I has caused persistent and widespread uncertainty. This study estimated the maximum potential thyroid doses of inhaled 131 I in the early post-accident phase between March 12 and 23, 2011 by using the hourly measured data of the 137 Cs concentrations at 101 suspended particulate matter (SPM) monitoring sites, a new multi-model ensemble (MME) method of simulating 137 Cs concentrations using two Atmospheric Transport and Deposition Models (ATDMs), the 131 I/ 137 Cs ratio obtained from measurement data analysis, and the internal exposure model. Based on the measurements, the maximum potential thyroid doses were estimated at 3.1-160 mSv at 5 sites in the Fukushima-Hamadori area for 1-year-old children assumed to remain outdoors, whereas they were less than 4.3 mSv at the other sites in the base case of the 131 I/ 137 Cs ratio. The spatial distribution of the maximum potential of early inhalation doses was estimated by using the MME and measurements. The inhalation thyroid doses in the evacuation scenarios were compared to the estimates reported by previous studies. The results of the present study were almost congruent with the outcomes of previous investigations except for thyroid doses contributed by highly contaminated plumes on March 12 and 15. The sensitivity analysis for the 131 I/ 137 Cs ratio indicated that these plumes carried the potential to significantly increase the thyroid doses of residents., Competing Interests: Declaration of competing interest The authors have no conflicts of interest to declare., (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)